Evidence map›Paper›PMID 41994187›Full record

ReviewIJTLD open2026

Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review.

M Amiri, M Cheraghi, M J Nasiri, D R Silva, G Sotgiu, L D'Ambrosio, R Centis, I Kontsevaya, H K Gandhi, D Oberdhan and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M AmiriDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
M CheraghiDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
M J NasiriDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
D R SilvaFaculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
G SotgiuClinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
L D'AmbrosioPublic Health Consulting Group, Lugano, Switzerland.
R CentisServizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy.
I KontsevayaOtsuka Novel Products GmbH, Munich, Germany.
H K GandhiOtsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
D OberdhanOtsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
V GirbingerOtsuka Novel Products GmbH, Munich, Germany.
M DaraOtsuka Novel Products GmbH, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA previous review summarised the evolution and efficacy of the regimens to treat rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), underscoring the persistent need for efficacious shorter treatments. The aim of this scoping review was to explore safety, quality of life (QoL), and unmet needs associated with RR/MDR-TB in studies published between 2009 and 2024.

methodsWe searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science for studies reporting safety, QoL, and unmet needs in the last 15 years.

resultsFifty-seven studies including 9,874 patients were identified, with significant variation in geographic distribution, sample size, and other core variables. The overall proportion of serious adverse events (AEs) ranged between 0.2% and 10.1% in retrospective studies, 1.0%-72.4% in prospective cohorts, and 20.0%-25.0% in experimental studies, with no data on QoL. Almost all studies containing linezolid (LZD) reported gastrointestinal and haematological AEs. In studies based on individual patient data, AEs associated with bedaquiline (1.7%-2.4%) and fluoroquinolones (3%-4%) were less frequent than those associated with LZD (14.1%-17.2%). The World Health Organization 95% credible interval range was 10.1%-27.0%.

conclusionWhile efficacious RR/MDR-TB regimens are recommended, individual drugs still cause AEs potentially leading to decreased adherence. New efficacious treatments with improved safety/tolerability profiles are needed.

Indexed as

adverse eventsDR-TBMDR-TBmeta-analysistolerabilitytuberculosis

Identifiers

PMID41994187
PMCPMC13080302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.